Abstract
The neurotrophins neurotrophin-3 (NT-3), brain-derived growth factor (BDNF) and nerve growth factor (NGF) bind to the p75 receptor, but each neurotrophin also binds a more selective Trk receptor (e.g. TrkA-NGF and TrkC-NT-3). The biochemical signals following engagement of either Trk or p75 with ligands are well understood, but long-term biological outcomes (trophic, proapoptotic or differentiative) remain unclear because they are cell/tissue specific. For example, Trk receptors are usually trophic but when overexpressed they can be proapoptotic in neuroblastomas and medulloblastomas. We hypothesized that coexpression of Trk and p75 receptors may lead to cross-regulation of signals and different biological outcomes; and used receptor-selective ligands to study cross-regulation by these receptors. We show that in the absence of Trk activation, expression of TrkC is permissive of p75 trophic and differentiation signals induced by p75 ligands, whereas expression of TrkA abolishes trophic and differentiation signals induced by p75 ligands. In contrast, in the presence of Trk activation, p75 ligands can regulate TrkA-mediated survival and TrkC-mediated differentiation. Therefore, a complex homeostasis of p75-selective and Trk-selective signals may determine the fate of cells expressing both receptors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Atwal JK, Massie B, Miller FD and Kaplan DR . (2000). Neuron, 27, 265–277.
Bamji SX, Majdan M, Pozniak CD, Belliveau DJ, Aloyz R, Kohn J, Causing CG and Miller FD . (1998). J. Cell Biol., 140, 911–923.
Barker PA . (1998). Cell Death Differ., 5, 346–356.
Baskey JC, Kalisch BE, Davis WL, Meakin SO and Rylett RJ . (2002). J. Neurochem., 80, 501–511.
Bhakar AL, Roux PP, Lachance C, Kryl D, Zeindler C and Barker PA . (1999). J. Biol. Chem., 274, 21443–21449.
Bibel M, Hoppe E and Barde Y-A . (1999). EMBO J., 18, 616–622.
Bilderback TR, Gazula VR and Dobrowsky RT . (2001). J. Neurochem., 76, 1540–1551.
Brann AB, Scott R, Neuberger Y, Abulafia D, Boldin S, Fainzilber M and Futerman AH . (1999). J. Neurosci., 19, 8199–8206.
Brann AB, Tcherpakov M, Williams IM, Futerman AH and Fainzilber M . (2002). J. Biol. Chem., 277, 9812–9818.
Bredesen DE and Rabizadeh S . (1997). Trends Neurosci., 20, 287–290.
Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG, Lee CP and Evans AE . (1997). J. Neuro-Oncol., 31, 49–55.
Casaccia-Bonnefil P, Carter BD, Dobrowsky RT and Chao MV . (1996). Nature, 383, 716–719.
Chao M, Casaccia-Bonnefil P, Carter B, Chittka A, Kong H and Yoon S . (1998a). Brain Res. Brain Res. Rev., 26, 295–301.
Chao M, Casaccia-Bonnefil P, Carter B, Chittka A, Kong H and Yoon SO . (1998b). Brain Res. Rev., 26, 295–301.
Dechant G, Tsoulfas P, Parada LF and Barde Y-A . (1997). J. Neurosci., 17, 5281–5287.
Esposito D, Patel P, Stephens RM, Perez P, Chao MV, Kaplan DR and Hempstead BL . (2001). J. Biol. Chem., 276, 32687–32695.
Frade JM and Barde YA . (1998). Bioessays, 20, 137–145.
Gentry JJ, Casaccia-Bonnefil P and Carter BD . (2000). J. Biol. Chem., 275, 7558–7565.
Hapner SJ, Boeshore KL, Large TH and Lefcort F . (1998). Dev. Biol., 201, 90–100.
Hempstead B . (2002). Curr. Opin. Neurobiol., 12, 260–267.
Hirata H, Hibasami H, Yoshida T, Ogawa M, Matsumoto M, Morita A and Uchida A . (2001). GLIA, 36, 245–258.
Ito H, Nomoto H and Furukawa S . (2003). J. Neurosci. Res., 72, 211–217.
Kaplan DR and Miller FD . (2000). Curr. Opin. Neurobiol., 10, 381–391.
Kaplan DR and Stephens RM . (1994). J. Neurobiol., 25, 1404–1417.
Kramer K, Gerald W, LeSauteur L, Saragovi HU and Cheung N-KV . (1997). Eur. J. Cancer, 33, 2090–2091.
Kuner P and Hertel C . (1998). J. Neurosci. Res., 54, 465–474.
Kuner P, Schubenel R and Hertel C . (1998). J. Neurosci. Res., 54, 798–804.
Lachyankar MB, Condon PJ, Daou MC, De AK, Levine JB, Obermeier A and Ross AH . (2003). J. Neurosci. Res., 71, 157–172.
Lee R, Kermani P, Teng KK and Hempstead BL . (2001). Science, 294, 1945–1948.
MacDonald JIS and Meakin SO . (1996). Mol. Cell. Neurosci., 7, 371–390.
MacPhee IJ and Barker PA . (1997). J. Biol. Chem., 272, 23547–23551.
Mahadeo D, Kaplan D, Chao M and Hempstead B . (1994). J. Biol. Chem., 269, 6884–6991.
Maliartchouk S and Saragovi HU . (1997). J. Neurosci., 17, 6031–6037.
Meakin SO, MacDonald JIS, Gryz EA, Kubu CJ and Verdi JM . (1999). J. Biol. Chem., 274, 9861–9870.
Postigo A, Calella AM, Fritzsch B, Knipper M, Katz D, Eilers A, Schimmang T, Lewin GR, Klein R and Minichiello L . (2002). Genes Dev., 16, 633–645.
Rabizadeh S, Ye X, Wang JJ and Bredesen DE . (1999). Cell Death Differ., 6, 1222–1227.
Romashkova JA and Makarov SS . (1999). Nature, 401, 86–90.
Roux PP, Bhakar AL, Kennedy TE and Barker PA . (2001). J. Biol. Chem., 276, 23097–23104.
Saragovi U, Zheng W, Maliartchouk S, DiGugliemo GM, Mawal Y, Kamen A, Woo SB, Cuello AC, Debeir T and Neet KE . (1998). J. Biol. Chem., 273, 34933–34940.
Sarmiere PD and Freeman RS . (2001). Mol. Cell. Neurosci., 18, 320–331.
Schubert KM, Scheid MP and Duronio V . (2000). J. Biol. Chem., 275, 13330–13335.
Urdiales JL, Becker E, Andrieu M, Thomas A, Jullien J, van Grunsven LA, Menut S, Evan GI, Martin-Zanca D and Rudkin BB . (1998). J. Neurosci., 18, 6767–6775.
Vesa J, Kruttgen A and Shooter EM . (2000). J. Biol. Chem., 275, 24414–24420.
Yamashiro DJ, Nakagawara A, Ikegaki N, Liu XG and Brodeur GM . (1996). Oncogene, 12, 37–41.
Yamashita T, Higuchi H and Tohyama M . (2002). J. Cell Biol., 157, 565–570.
Yan C, Liang Y, Nylander KD, Wong J, Rudavsky RM, Saragovi HU and Schor NF . (2002). Mol. Pharmacol., 61, 710–719.
Zaccaro M, Ivanisevic L, Perez P, Meakin S and Saragovi H . (2001). J. Biol. Chem., 276, 31023–31029.
Acknowledgements
We thank Dr Michael Fainzilber (Weizmann Institute, Israel) for reviewing the manuscript and Drs Phil Barker (McGill University, Canada) and Susan Meakin (Robarts Institute, Canada) for reagents. This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and from the National Institute of Neurological Disease and Stroke (Grant #: R01-NS38569) to HUS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ivanisevic, L., Banerjee, K. & Saragovi, H. Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75. Oncogene 22, 5677–5685 (2003). https://doi.org/10.1038/sj.onc.1206864
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206864
Keywords
This article is cited by
-
Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo
Cancer Chemotherapy and Pharmacology (2010)
-
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex
Nature Neuroscience (2004)